. 2019 Feb 22;53(3):223–230. doi: 10.1007/s13139-019-00579-w

Table 2.

Biochemical data across all time points for patient B

	June 2014 Presentation	October 2014 Pre-treatment	March 2016 Post-treatment	April 2016 Follow-Up
Plasma metanephrine [URL 450 pmol/L]	123 (< 1.0×)	158 (< 1.0×)	149 (< 1.0×)	182 (< 1.0×)
Plasma normetanephrine [URL 747 pmol/L]	314 (< 1.0×)	315 (< 1.0×)	244 (< 1.0×)	543 (< 1.0×)
Plasma 3-methoxytyramine [URL 100 pmol/L]	< 100 (< 1.0×)	< 100 (< 1.0×)	106 (1.1×)	147 (1.5×)
Chromogranin A [URL 100 mcg/mL]	865 (8.7×)	958 (9.6×)	2780 (27.8×)	13,020 (130.2×)

June 2014
Presentation

October 2014
Pre-treatment

March 2016
Post-treatment

April 2016
Follow-Up

Plasma metanephrine

[URL 450 pmol/L]

123

(< 1.0×)

158

(< 1.0×)

149

(< 1.0×)

182

(< 1.0×)

Plasma normetanephrine

[URL 747 pmol/L]

314

(< 1.0×)

315

(< 1.0×)

244

(< 1.0×)

543

(< 1.0×)

Plasma

3-methoxytyramine

[URL 100 pmol/L]

< 100

(< 1.0×)

< 100

(< 1.0×)

106

(1.1×)

147

(1.5×)

Chromogranin A

[URL 100 mcg/mL]

865

(8.7×)

958

(9.6×)

2780

(27.8×)

13,020

(130.2×)

Abbreviations: URL, upper reference limit

Values in parentheses represent multiples of the upper reference limit